Physician profile
Boris Khorets
NPI 1619989514
$12,140.86
in general payments reported to CMS, 2019-2025
48 companies · $1,494 in 2025
The $1,494 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,483 · 2020: $1,386 · 2021: $2,718 · 2022: $2,223 · 2023: $688 · 2024: $1,149 · 2025: $1,494.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,331.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,330.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,272.87 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,021.94 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $697.80 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $642.60 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Amgen INC. | $581.40 | 2019-2025 | Otezla, Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $558.72 | 2021-2023 | |
| Horizon Therapeutics Plc | $501.27 | 2019-2022 | |
| Aimmune Therapeutics, INC. | $474.61 | 2025 | Zenpep |
| Astrazeneca Pharmaceuticals LP | $443.18 | 2020-2025 | Farxiga, Breztri |
| Amarin Pharma, INC. | $433.03 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $395.70 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $389.01 | 2019-2022 | |
| Pfizer INC. | $384.30 | 2019-2025 | |
| Lilly USA, LLC | $347.36 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| E.R. Squibb & Sons, L.L.C. | $294.06 | 2019-2025 | Eliquis |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Boris Khorets listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.